Brief: Immuneering Reports Compelling Preclinical Data On IMM-1-104 In NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event
06/01/2022 22:20
Jan 6 (Reuters) - Immuneering Corp IMRX.O :
* IMMUNEERING REPORTS COMPELLING PRECLINICAL DATA ON
IMM-1-104 IN
NRAS MUTANT MELANOMA MODEL AND WILL HOST KEY EXTERNAL EXPERT
INVESTOR EVENT
Source text for Eikon: ID:nGNX9hS0TV
Further company coverage: IMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences